| Dr Amy D Carrillo, DO | |
|
170 N Eagle Creek Dr Ste 104, Lexington, KY 40509-9087 | |
| (859) 967-5848 | |
| (859) 967-5473 |
| Full Name | Dr Amy D Carrillo |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 20 Years |
| Location | 170 N Eagle Creek Dr Ste 104, Lexington, Kentucky |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780878330 | NPI | - | NPPES |
| 41954515 | Other | TN | BLUE CROSS BLUE SHIELD OF TN |
| 7100314440 (KOHMG) | Medicaid | KY | |
| 7100314440 | Medicaid | KY | |
| 1508408 | Medicaid | TN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | DO0000001939 (Tennessee) | Secondary |
| 207V00000X | Obstetrics & Gynecology | 03678 (Kentucky) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kentuckyone Health Medical Group Inc | 8820993702 | 227 |
News Archive
LSP (Life Sciences Partners), the specialist healthcare investment firm, has announced today a strategic collaboration with Bristol-Myers Squibb Company in which the companies will work closely together in identifying European breakthrough technologies and products in immuno-oncology and other areas of unmet medical need.
Today, Zealand Pharma, a Copenhagen based biopharmaceutical company, and Boehringer Ingelheim, one of the world's leading pharmaceutical companies, jointly announced an exclusive global licence and collaboration agreement for dual-acting glucagon and GLP-1 receptor agonists for the treatment of patients with Type-2 diabetes and patients with obesity.
ViroPharma is increasing its Cinryze manufacturing capacity through two concurrent efforts. The first project, the parallel chromatography process, was implemented earlier this year and allows production to run across multiple shifts, effectively doubling the capacity of the current manufacturing line and increasing the amount of drug supply available to patients suffering from hereditary angioedema, or HAE.
Research, conducted by experts at the Centre for Drug Misuse Research at the University of Glasgow, involving a survey of 2,318 ten to twelve year olds in Glasgow and Newcastle, reveals a unique insight into the factors behind illegal drug use by preteen children
› Verified 1 days ago
| Entity Name | Kentuckyone Health Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104875970 PECOS PAC ID: 8820993702 Enrollment ID: O20031204000080 |
News Archive
LSP (Life Sciences Partners), the specialist healthcare investment firm, has announced today a strategic collaboration with Bristol-Myers Squibb Company in which the companies will work closely together in identifying European breakthrough technologies and products in immuno-oncology and other areas of unmet medical need.
Today, Zealand Pharma, a Copenhagen based biopharmaceutical company, and Boehringer Ingelheim, one of the world's leading pharmaceutical companies, jointly announced an exclusive global licence and collaboration agreement for dual-acting glucagon and GLP-1 receptor agonists for the treatment of patients with Type-2 diabetes and patients with obesity.
ViroPharma is increasing its Cinryze manufacturing capacity through two concurrent efforts. The first project, the parallel chromatography process, was implemented earlier this year and allows production to run across multiple shifts, effectively doubling the capacity of the current manufacturing line and increasing the amount of drug supply available to patients suffering from hereditary angioedema, or HAE.
Research, conducted by experts at the Centre for Drug Misuse Research at the University of Glasgow, involving a survey of 2,318 ten to twelve year olds in Glasgow and Newcastle, reveals a unique insight into the factors behind illegal drug use by preteen children
› Verified 1 days ago
| Entity Name | Healthfirst Bluegrass Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114932514 PECOS PAC ID: 5890961593 Enrollment ID: O20111230000186 |
News Archive
LSP (Life Sciences Partners), the specialist healthcare investment firm, has announced today a strategic collaboration with Bristol-Myers Squibb Company in which the companies will work closely together in identifying European breakthrough technologies and products in immuno-oncology and other areas of unmet medical need.
Today, Zealand Pharma, a Copenhagen based biopharmaceutical company, and Boehringer Ingelheim, one of the world's leading pharmaceutical companies, jointly announced an exclusive global licence and collaboration agreement for dual-acting glucagon and GLP-1 receptor agonists for the treatment of patients with Type-2 diabetes and patients with obesity.
ViroPharma is increasing its Cinryze manufacturing capacity through two concurrent efforts. The first project, the parallel chromatography process, was implemented earlier this year and allows production to run across multiple shifts, effectively doubling the capacity of the current manufacturing line and increasing the amount of drug supply available to patients suffering from hereditary angioedema, or HAE.
Research, conducted by experts at the Centre for Drug Misuse Research at the University of Glasgow, involving a survey of 2,318 ten to twelve year olds in Glasgow and Newcastle, reveals a unique insight into the factors behind illegal drug use by preteen children
› Verified 1 days ago
| Entity Name | Obhg Kentucky Psc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457644122 PECOS PAC ID: 5496910200 Enrollment ID: O20120628000666 |
News Archive
LSP (Life Sciences Partners), the specialist healthcare investment firm, has announced today a strategic collaboration with Bristol-Myers Squibb Company in which the companies will work closely together in identifying European breakthrough technologies and products in immuno-oncology and other areas of unmet medical need.
Today, Zealand Pharma, a Copenhagen based biopharmaceutical company, and Boehringer Ingelheim, one of the world's leading pharmaceutical companies, jointly announced an exclusive global licence and collaboration agreement for dual-acting glucagon and GLP-1 receptor agonists for the treatment of patients with Type-2 diabetes and patients with obesity.
ViroPharma is increasing its Cinryze manufacturing capacity through two concurrent efforts. The first project, the parallel chromatography process, was implemented earlier this year and allows production to run across multiple shifts, effectively doubling the capacity of the current manufacturing line and increasing the amount of drug supply available to patients suffering from hereditary angioedema, or HAE.
Research, conducted by experts at the Centre for Drug Misuse Research at the University of Glasgow, involving a survey of 2,318 ten to twelve year olds in Glasgow and Newcastle, reveals a unique insight into the factors behind illegal drug use by preteen children
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Amy D Carrillo, DO Po Box 936, London, KY 40743-0936 Ph: (606) 330-7840 | Dr Amy D Carrillo, DO 170 N Eagle Creek Dr Ste 104, Lexington, KY 40509-9087 Ph: (859) 967-5848 |
News Archive
LSP (Life Sciences Partners), the specialist healthcare investment firm, has announced today a strategic collaboration with Bristol-Myers Squibb Company in which the companies will work closely together in identifying European breakthrough technologies and products in immuno-oncology and other areas of unmet medical need.
Today, Zealand Pharma, a Copenhagen based biopharmaceutical company, and Boehringer Ingelheim, one of the world's leading pharmaceutical companies, jointly announced an exclusive global licence and collaboration agreement for dual-acting glucagon and GLP-1 receptor agonists for the treatment of patients with Type-2 diabetes and patients with obesity.
ViroPharma is increasing its Cinryze manufacturing capacity through two concurrent efforts. The first project, the parallel chromatography process, was implemented earlier this year and allows production to run across multiple shifts, effectively doubling the capacity of the current manufacturing line and increasing the amount of drug supply available to patients suffering from hereditary angioedema, or HAE.
Research, conducted by experts at the Centre for Drug Misuse Research at the University of Glasgow, involving a survey of 2,318 ten to twelve year olds in Glasgow and Newcastle, reveals a unique insight into the factors behind illegal drug use by preteen children
› Verified 1 days ago
Dr. Allison Leigh Swiecki-sikora, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 800 Rose St, Lexington, KY 40536 Phone: 859-323-6434 | |
Mrs. Jennifer A Fuson, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1720 Nicholasville Rd, Ste 702, Lexington, KY 40503 Phone: 859-264-8811 Fax: 859-264-8822 | |
Tracey Owensby Carbajal, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1700 Nicholasville Rd, Suite 701, Lexington, KY 40503 Phone: 859-278-0396 Fax: 859-278-0396 | |
Larry S. Butler, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3213 Summit Square Pl, Suite 200, Lexington, KY 40509 Phone: 859-381-1066 Fax: 859-263-0650 | |
Elizabeth Shawn Campbell, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 211 Fountain Ct Ste 230, Lexington, KY 40509 Phone: 859-629-7200 Fax: 859-629-7212 | |
Tenley Mckee Atwater, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 800 Rose St, Lexington, KY 40536 Phone: 859-257-8801 Fax: 859-257-2828 | |
Dr. Rudolph Michael Tovar, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 800 Rose Street Rm. C-358, Lexington, KY 40536 Phone: 859-257-2321 Fax: 859-257-9089 |